This study is designed as a Phase II, multicenter, single arm trial to assess anti-B Cell
Maturation Antigen (BCMA) chimeric antigen receptor (CAR) T-cells (bb2121) to improve post
autologous hematopoietic cell transplant (HCT) responses among patients with multiple myeloma
(MM).
Phase:
Phase 2
Details
Lead Sponsor:
Marcelo Pasquini, MD
Collaborators:
Blood and Marrow Transplant Clinical Trials Network Celgene a wholly owned subsidiary of BMS Celgene Corporation National Cancer Institute (NCI) National Heart, Lung, and Blood Institute (NHLBI) National Marrow Donor Program